Abbott's Esprit BTK Dissolvable Stent Approved By Health Canada
I'm PortAI, I can summarize articles.
Abbott Laboratories has received approval from Health Canada for its Esprit BTK Everolimus Eluting Resorbable Scaffold System, a dissolvable stent designed to treat chronic limb threatening ischemia (CLTI) below-the-knee. This device helps keep arteries open and delivers the drug everolimus to aid healing before it fully dissolves, addressing the needs of over 800,000 Canadians suffering from Peripheral Artery Disease (PAD).
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments